Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 14 de 14
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Epilepsia ; 65(5): 1394-1405, 2024 May.
Artigo em Inglês | MEDLINE | ID: mdl-38441332

RESUMO

OBJECTIVE: This study was undertaken to characterize changes in health care utilization and mortality for people with epilepsy (PWE) during the COVID-19 pandemic. METHODS: We performed a retrospective study using linked, individual-level, population-scale anonymized health data from the Secure Anonymised Information Linkage databank. We identified PWE living in Wales during the study "pandemic period" (January 1, 2020-June 30, 2021) and during a "prepandemic" period (January 1, 2016-December 31, 2019). We compared prepandemic health care utilization, status epilepticus, and mortality rates with corresponding pandemic rates for PWE and people without epilepsy (PWOE). We performed subgroup analyses on children (<18 years old), older people (>65 years old), those with intellectual disability, and those living in the most deprived areas. We used Poisson models to calculate adjusted rate ratios (RRs). RESULTS: We identified 27 279 PWE who had significantly higher rates of hospital (50.3 visits/1000 patient months), emergency department (55.7), and outpatient attendance (172.4) when compared to PWOE (corresponding figures: 25.7, 25.2, and 87.0) in the prepandemic period. Hospital and epilepsy-related hospital admissions, and emergency department and outpatient attendances all reduced significantly for PWE (and all subgroups) during the pandemic period. RRs [95% confidence intervals (CIs)] for pandemic versus prepandemic periods were .70 [.69-.72], .77 [.73-.81], .78 [.77-.79], and .80 [.79-.81]. The corresponding rates also reduced for PWOE. New epilepsy diagnosis rates decreased during the pandemic compared with the prepandemic period (2.3/100 000/month cf. 3.1/100 000/month, RR = .73, 95% CI = .68-.78). Both all-cause deaths and deaths with epilepsy recorded on the death certificate increased for PWE during the pandemic (RR = 1.07, 95% CI = .997-1.145 and RR = 2.44, 95% CI = 2.12-2.81). When removing COVID deaths, RRs were .88 (95% CI = .81-.95) and 1.29 (95% CI = 1.08-1.53). Status epilepticus rates did not change significantly during the pandemic (RR = .95, 95% CI = .78-1.15). SIGNIFICANCE: All-cause non-COVID deaths did not increase but non-COVID deaths associated with epilepsy did increase for PWE during the COVID-19 pandemic. The longer term effects of the decrease in new epilepsy diagnoses and health care utilization and increase in deaths associated with epilepsy need further research.


Assuntos
COVID-19 , Epilepsia , Aceitação pelo Paciente de Cuidados de Saúde , Humanos , COVID-19/epidemiologia , COVID-19/mortalidade , Epilepsia/epidemiologia , Epilepsia/mortalidade , Feminino , Masculino , Estudos Retrospectivos , Idoso , Adolescente , Criança , Adulto , Aceitação pelo Paciente de Cuidados de Saúde/estatística & dados numéricos , Pessoa de Meia-Idade , Adulto Jovem , País de Gales/epidemiologia , Pré-Escolar , Estado Epiléptico/mortalidade , Estado Epiléptico/epidemiologia , Hospitalização/estatística & dados numéricos , Lactente , Pandemias , Serviço Hospitalar de Emergência/estatística & dados numéricos , Deficiência Intelectual/epidemiologia , Deficiência Intelectual/mortalidade , Idoso de 80 Anos ou mais
2.
Epilepsia ; 65(5): 1383-1393, 2024 May.
Artigo em Inglês | MEDLINE | ID: mdl-38441374

RESUMO

OBJECTIVE: People with epilepsy (PWE) may be at an increased risk of severe COVID-19. It is important to characterize this risk to inform PWE and for future health and care planning. We assessed whether PWE were at higher risk of being hospitalized with, or dying from, COVID-19. METHODS: We performed a retrospective cohort study using linked, population-scale, anonymized electronic health records from the SAIL (Secure Anonymised Information Linkage) databank. This includes hospital admission and demographic data for the complete Welsh population (3.1 million) and primary care records for 86% of the population. We identified 27 279 PWE living in Wales during the study period (March 1, 2020 to June 30, 2021). Controls were identified using exact 5:1 matching (sex, age, and socioeconomic status). We defined COVID-19 deaths as having International Classification of Diseases, 10th Revision (ICD-10) codes for COVID-19 on death certificates or occurring within 28 days of a positive SARS-CoV-2 polymerase chain reaction (PCR) test. COVID-19 hospitalizations were defined as having a COVID-19 ICD-10 code for the reason for admission or occurring within 28 days of a positive SARS-CoV-2 PCR test. We recorded COVID-19 vaccinations and comorbidities known to increase the risk of COVID-19 hospitalization and death. We used Cox proportional hazard models to calculate hazard ratios. RESULTS: There were 158 (.58%) COVID-19 deaths and 933 (3.4%) COVID-19 hospitalizations in PWE, and 370 (.27%) deaths and 1871 (1.4%) hospitalizations in controls. Hazard ratios for COVID-19 death and hospitalization in PWE compared to controls were 2.15 (95% confidence interval [CI] = 1.78-2.59) and 2.15 (95% CI = 1.94-2.37), respectively. Adjusted hazard ratios (adjusted for comorbidities) for death and hospitalization were 1.32 (95% CI = 1.08-1.62) and 1.60 (95% CI = 1.44-1.78). SIGNIFICANCE: PWE are at increased risk of being hospitalized with, and dying from, COVID-19 when compared to age-, sex-, and deprivation-matched controls, even when adjusting for comorbidities. This may have implications for prioritizing future COVID-19 treatments and vaccinations for PWE.


Assuntos
COVID-19 , Epilepsia , Hospitalização , Humanos , COVID-19/mortalidade , COVID-19/epidemiologia , Feminino , Masculino , Hospitalização/estatística & dados numéricos , Epilepsia/epidemiologia , Epilepsia/mortalidade , Pessoa de Meia-Idade , Adulto , Estudos Retrospectivos , Idoso , País de Gales/epidemiologia , Adulto Jovem , Fatores de Risco , Adolescente , Estudos de Coortes , Idoso de 80 Anos ou mais , Comorbidade , SARS-CoV-2
3.
Epilepsia ; 64(11): 3099-3108, 2023 11.
Artigo em Inglês | MEDLINE | ID: mdl-37643892

RESUMO

OBJECTIVE: This study was undertaken to develop a novel pathway linking genetic data with routinely collected data for people with epilepsy, and to analyze the influence of rare, deleterious genetic variants on epilepsy outcomes. METHODS: We linked whole-exome sequencing (WES) data with routinely collected primary and secondary care data and natural language processing (NLP)-derived seizure frequency information for people with epilepsy within the Secure Anonymised Information Linkage Databank. The study participants were adults who had consented to participate in the Swansea Neurology Biobank, Wales, between 2016 and 2018. DNA sequencing was carried out as part of the Epi25 collaboration. For each individual, we calculated the total number and cumulative burden of rare and predicted deleterious genetic variants and the total of rare and deleterious variants in epilepsy and drug metabolism genes. We compared these measures with the following outcomes: (1) no unscheduled hospital admissions versus unscheduled admissions for epilepsy, (2) antiseizure medication (ASM) monotherapy versus polytherapy, and (3) at least 1 year of seizure freedom versus <1 year of seizure freedom. RESULTS: We linked genetic data for 107 individuals with epilepsy (52% female) to electronic health records. Twenty-six percent had unscheduled hospital admissions, and 70% were prescribed ASM polytherapy. Seizure frequency information was linked for 100 individuals, and 10 were seizure-free. There was no significant difference between the outcome groups in terms of the exome-wide and gene-based burden of rare and deleterious genetic variants. SIGNIFICANCE: We successfully uploaded, annotated, and linked genetic sequence data and NLP-derived seizure frequency data to anonymized health care records in this proof-of-concept study. We did not detect a genetic influence on real-world epilepsy outcomes, but our study was limited by a small sample size. Future studies will require larger (WES) data to establish genetic variant contribution to epilepsy outcomes.


Assuntos
Epilepsia , Adulto , Humanos , Feminino , Masculino , Sequenciamento do Exoma , Epilepsia/tratamento farmacológico , Epilepsia/genética , Convulsões/tratamento farmacológico , Atenção à Saúde , Armazenamento e Recuperação da Informação , Anticonvulsivantes/uso terapêutico
4.
Am J Hum Genet ; 108(1): 176-185, 2021 01 07.
Artigo em Inglês | MEDLINE | ID: mdl-33245860

RESUMO

Fibroblast growth factor homologous factors (FHFs) are intracellular proteins which regulate voltage-gated sodium (Nav) channels in the brain and other tissues. FHF dysfunction has been linked to neurological disorders including epilepsy. Here, we describe two sibling pairs and three unrelated males who presented in infancy with intractable focal seizures and severe developmental delay. Whole-exome sequencing identified hemi- and heterozygous variants in the N-terminal domain of the A isoform of FHF2 (FHF2A). The X-linked FHF2 gene (also known as FGF13) has alternative first exons which produce multiple protein isoforms that differ in their N-terminal sequence. The variants were located at highly conserved residues in the FHF2A inactivation particle that competes with the intrinsic fast inactivation mechanism of Nav channels. Functional characterization of mutant FHF2A co-expressed with wild-type Nav1.6 (SCN8A) revealed that mutant FHF2A proteins lost the ability to induce rapid-onset, long-term blockade of the channel while retaining pro-excitatory properties. These gain-of-function effects are likely to increase neuronal excitability consistent with the epileptic potential of FHF2 variants. Our findings demonstrate that FHF2 variants are a cause of infantile-onset developmental and epileptic encephalopathy and underline the critical role of the FHF2A isoform in regulating Nav channel function.


Assuntos
Encefalopatias/genética , Epilepsia/genética , Fatores de Crescimento de Fibroblastos/genética , Mutação de Sentido Incorreto/genética , Isoformas de Proteínas/genética , Adolescente , Sequência de Aminoácidos , Criança , Éxons/genética , Feminino , Mutação com Ganho de Função/genética , Genes Ligados ao Cromossomo X/genética , Heterozigoto , Humanos , Masculino , Canal de Sódio Disparado por Voltagem NAV1.6/genética , Neurônios/fisiologia , Convulsões/genética
5.
Epilepsy Behav ; 111: 107196, 2020 10.
Artigo em Inglês | MEDLINE | ID: mdl-32554230

RESUMO

OBJECTIVE: The objective of the study was to assess the long-term outcomes of epilepsy surgery between 1995 and 2015 in South Wales, UK, linking case note review, postal questionnaire, and routinely collected healthcare data. METHOD: We identified patients from a departmental database and collected outcome data from patient case notes, a postal questionnaire, and the QOLIE-31-P and linked with Welsh routinely collected data in the Secure Anonymised Information Linkage (SAIL) databank. RESULTS: Fifty-seven patients were included. Median age at surgery was 34 years (11-70), median: 24 years (2-56) after onset of habitual seizures. Median follow-up was 7 years (2-19). Twenty-eight (49%) patients were free from disabling seizures (Engel Class 1), 9 (16%) experienced rare disabling seizures (Class 2), 13 (23%) had worthwhile improvements (Class 3), and 7 (12%) had no improvement (Class 4). There was a 30% mean reduction in total antiepileptic drug (AED) load at five years postsurgery. Thirty-eight (66.7%) patients experienced tonic-clonic seizures presurgery verses 8 (14%) at last review. Seizure-free patients self-reported a greater overall quality of life (QOL; QOLIE-31-P) when compared with those not achieving seizure freedom. Seizure-free individuals scored a mean of 67.6/100 (100 is best), whereas those with continuing seizures scored 46.0/100 (p < 0.006). There was a significant decrease in the median rate of hospital admissions for any cause after epilepsy surgery (9.8 days per 1000 patient days before surgery compared with 3.9 after p < 0.005). SIGNIFICANCE: Epilepsy surgery was associated with significant improvements in seizures, a reduced AED load, and an improved QOL that closely correlated with seizure outcomes and reduced hospital admission rates following surgery. Despite this, there was a long delay from onset of habitual seizures to surgery. The importance of long-term follow-up is emphasized in terms of evolving medical needs and health and social care outcomes.


Assuntos
Análise de Dados , Epilepsia/cirurgia , Aceitação pelo Paciente de Cuidados de Saúde , Medidas de Resultados Relatados pelo Paciente , Inquéritos e Questionários , Adolescente , Adulto , Idoso , Criança , Estudos de Coortes , Epilepsia/epidemiologia , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Estudos Retrospectivos , Fatores de Tempo , Resultado do Tratamento , País de Gales/epidemiologia , Adulto Jovem
6.
J Neurol ; 265(9): 2162-2163, 2018 09.
Artigo em Inglês | MEDLINE | ID: mdl-30132064
8.
EBioMedicine ; 2(9): 1063-70, 2015 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-26501104

RESUMO

Sudden unexpected death in epilepsy (SUDEP) represents the most severe degree of the spectrum of epilepsy severity and is the commonest cause of epilepsy-related premature mortality. The precise pathophysiology and the genetic architecture of SUDEP remain elusive. Aiming to elucidate the genetic basis of SUDEP, we analysed rare, protein-changing variants from whole-exome sequences of 18 people who died of SUDEP, 87 living people with epilepsy and 1479 non-epilepsy disease controls. Association analysis revealed a significantly increased genome-wide polygenic burden per individual in the SUDEP cohort when compared to epilepsy (P = 5.7 × 10(- 3)) and non-epilepsy disease controls (P = 1.2 × 10(- 3)). The polygenic burden was driven both by the number of variants per individual, and over-representation of variants likely to be deleterious in the SUDEP cohort. As determined by this study, more than a thousand genes contribute to the observed polygenic burden within the framework of this study. Subsequent gene-based association analysis revealed five possible candidate genes significantly associated with SUDEP or epilepsy, but no one single gene emerges as common to the SUDEP cases. Our findings provide further evidence for a genetic susceptibility to SUDEP, and suggest an extensive polygenic contribution to SUDEP causation. Thus, an overall increased burden of deleterious variants in a highly polygenic background might be important in rendering a given individual more susceptible to SUDEP. Our findings suggest that exome sequencing in people with epilepsy might eventually contribute to generating SUDEP risk estimates, promoting stratified medicine in epilepsy, with the eventual aim of reducing an individual patient's risk of SUDEP.


Assuntos
Epilepsia/genética , Variação Genética , Estudo de Associação Genômica Ampla/métodos , Herança Multifatorial/genética , Adulto , Causas de Morte , Morte Súbita , Epilepsia/mortalidade , Epilepsia/patologia , Exoma/genética , Feminino , Estudos de Associação Genética/métodos , Predisposição Genética para Doença/genética , Humanos , Masculino , Fatores de Risco , Análise de Sequência de DNA/métodos , Índice de Gravidade de Doença
9.
Epilepsia ; 56(4): 585-91, 2015 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-25873180

RESUMO

OBJECTIVE: To investigate whether the link between epilepsy and deprivation is due to factors associated with deprivation (social causation) or factors associated with a diagnosis of epilepsy (social drift). METHODS: We reviewed electronic primary health care records from 2004 to 2010, identifying prevalent and incident cases of epilepsy and recording linked deprivation scores. Logistic and Poisson regression models were used to calculate odds ratios and incidence rate ratios. The change in deprivation was measured 10 years after the initial diagnosis of epilepsy for a cohort of people. RESULTS: Between 2004 and 2010, 8.1 million patient-years of records were reviewed. Epilepsy prevalence and incidence were significantly associated with deprivation. Epilepsy prevalence ranged from 1.13% (1.07-1.19%) in the most deprived decile to 0.49% (0.45-0.53%) in the least deprived decile (adjusted odds ratio 0.92, p < 0.001). Epilepsy incidence ranged from 40/100,000 per year in the most deprived decile to 19/100,000 per year in the least deprived decile (adjusted incidence rate ratio 0.94, p < 0.001). There was no statistically significant change in deprivation index decile 10 years after a new diagnosis of epilepsy (mean difference -0.04, p = 0.85). SIGNIFICANCE: Epilepsy prevalence and incidence are strongly associated with deprivation; the deprivation score remains unchanged 10 years after a diagnosis of epilepsy. These findings suggest that increasing rates of epilepsy in deprived areas are more likely explained by social causation than by social drift. The nature of the association between incident epilepsy and social deprivation needs further exploration.


Assuntos
Coleta de Dados , Registros Eletrônicos de Saúde , Epilepsia/diagnóstico , Epilepsia/psicologia , Necessidades e Demandas de Serviços de Saúde , Carência Psicossocial , Adolescente , Adulto , Criança , Pré-Escolar , Estudos de Coortes , Epilepsia/epidemiologia , Feminino , Humanos , Lactente , Recém-Nascido , Masculino , Pessoa de Meia-Idade , País de Gales/epidemiologia , Adulto Jovem
10.
Epilepsia ; 55(10): 1634-41, 2014 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-25182657

RESUMO

OBJECTIVE: Epilepsy is more prevalent in areas of greater socioeconomic deprivation; however, the factors that comprise this deprivation are not understood. We aimed to investigate the association between epilepsy, individual elements of deprivation, and geographic region in order to identify modifiable elements. METHODS: Epilepsy prevalence was calculated via retrospective analysis of data recorded by general practitioners via the Quality and Outcomes Framework. The Index of Multiple Deprivation scores at Local Authority level for the entire population of England was employed. Epilepsy prevalence was evaluated for correlation against all seven indicators within the Indices of Multiple Deprivation. Data were analyzed including and excluding the city of London. RESULTS: Of the 37,699,503 patients in this study, 304,331 were registered as having epilepsy (prevalence 8 per 1,000; range 4.3-11.6). Positive correlation was seen with total Index of Multiple Deprivation score (r = 0.468, p < 0.01); education skills and training (r = 0.665, p < 0.01); employment deprivation (r = 0.629, p < 0.01); health deprivation and disability (r = 0.617, p < 0.01); income deprivation (r = 0.358, p < 0.01); crime (r = 0.232, p < 0.01); but not living environment (r = 0.079, p = 0.08). Negative correlation was seen between epilepsy prevalence and barriers to housing and services (r = -0.415, p < 0.01). When the data were analyzed excluding London, all correlations were strengthened. Epilepsy prevalence in adults varies by 2.5-fold across England, from 4.3 per 1,000 in Kensington and Chelsea to 11.6 per 1,000 in Blackpool. SIGNIFICANCE: This study shows a strong correlation between epilepsy prevalence and specific measures of socioeconomic deprivation. Many of these deprivation factors are potentially remediable. We hypothesize that people with epilepsy may move into urban areas and toward their general practitioner. This predominantly means an urban location but avoiding areas where the cost of living-particularly housing-is prohibitive, such as central London. The existing negative impact of epilepsy on employment and higher education may be exacerbated when people with epilepsy live in areas of greater socioeconomic deprivation.


Assuntos
Epilepsia/epidemiologia , Pobreza/estatística & dados numéricos , Adulto , Inglaterra/epidemiologia , Epilepsia/etiologia , Habitação/estatística & dados numéricos , Humanos , Londres/epidemiologia , Prevalência , Fatores Socioeconômicos
11.
Neurobiol Dis ; 64: 131-141, 2014 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-24407264

RESUMO

Genetic mutations in voltage-gated and ligand-gated ion channel genes have been identified in a small number of Mendelian families with genetic generalised epilepsies (GGEs). They are commonly associated with febrile seizures (FS), childhood absence epilepsy (CAE) and particularly with generalised or genetic epilepsy with febrile seizures plus (GEFS+). In clinical practice, despite efforts to categorise epilepsy and epilepsy families into syndromic diagnoses, many generalised epilepsies remain unclassified with a presumed genetic basis. During the systematic collection of epilepsy families, we assembled a cohort of families with evidence of GEFS+ and screened for variations in the γ2 subunit of the γ-aminobutyric acid (GABA) type A receptor gene (GABRG2). We detected a novel GABRG2(p.R136*) premature translation termination codon in one index-case from a two-generation nuclear family, presenting with an unclassified GGE, a borderline GEFS+ phenotype with learning difficulties and extended behavioural presentation. The GABRG2(p.R136*) mutation segregates with the febrile seizure component of this family's GGE and is absent in 190 healthy control samples. In vitro expression assays demonstrated that γ2(p.R136*) subunits were produced, but had reduced cell-surface and total expression. When γ2(p.R136*) subunits were co-expressed with α1 and ß2 subunits in HEK 293T cells, GABA-evoked currents were reduced. Furthermore, γ2(p.R136*) subunits were highly-expressed in intracellular aggregations surrounding the nucleus and endoplasmic reticulum (ER), suggesting compromised receptor trafficking. A novel GABRG2(p.R136*) mutation extends the spectrum of GABRG2 mutations identified in GEFS+ and GGE phenotypes, causes GABAA receptor dysfunction, and represents a putative epilepsy mechanism.


Assuntos
Epilepsia Generalizada/genética , Fenótipo , Mutação Puntual , Receptores de GABA-A/genética , Convulsões Febris/genética , Adulto , Animais , Células COS , Células Cultivadas , Córtex Cerebral/fisiopatologia , Criança , Pré-Escolar , Chlorocebus aethiops , Estudos de Coortes , Família , Feminino , Células HEK293 , Humanos , Lactente , Masculino , Neurônios/fisiologia , Células PC12 , Ratos , Receptores de GABA-A/metabolismo
12.
J Biol Chem ; 288(47): 33745-33759, 2013 Nov 22.
Artigo em Inglês | MEDLINE | ID: mdl-24108130

RESUMO

Hyperekplexia is a syndrome of readily provoked startle responses, alongside episodic and generalized hypertonia, that presents within the first month of life. Inhibitory glycine receptors are pentameric ligand-gated ion channels with a definitive and clinically well stratified linkage to hyperekplexia. Most hyperekplexia cases are caused by mutations in the α1 subunit of the human glycine receptor (hGlyR) gene (GLRA1). Here we analyzed 68 new unrelated hyperekplexia probands for GLRA1 mutations and identified 19 mutations, of which 9 were novel. Electrophysiological analysis demonstrated that the dominant mutations p.Q226E, p.V280M, and p.R414H induced spontaneous channel activity, indicating that this is a recurring mechanism in hGlyR pathophysiology. p.Q226E, at the top of TM1, most likely induced tonic activation via an enhanced electrostatic attraction to p.R271 at the top of TM2, suggesting a structural mechanism for channel activation. Receptors incorporating p.P230S (which is heterozygous with p.R65W) desensitized much faster than wild type receptors and represent a new TM1 site capable of modulating desensitization. The recessive mutations p.R72C, p.R218W, p.L291P, p.D388A, and p.E375X precluded cell surface expression unless co-expressed with α1 wild type subunits. The recessive p.E375X mutation resulted in subunit truncation upstream of the TM4 domain. Surprisingly, on the basis of three independent assays, we were able to infer that p.E375X truncated subunits are incorporated into functional hGlyRs together with unmutated α1 or α1 plus ß subunits. These aberrant receptors exhibit significantly reduced glycine sensitivity. To our knowledge, this is the first suggestion that subunits lacking TM4 domains might be incorporated into functional pentameric ligand-gated ion channel receptors.


Assuntos
Regulação da Expressão Gênica , Rigidez Muscular/metabolismo , Mutação de Sentido Incorreto , Receptores de Glicina/metabolismo , Substituição de Aminoácidos , Feminino , Humanos , Masculino , Rigidez Muscular/genética , Estrutura Secundária de Proteína , Estrutura Terciária de Proteína , Receptores de Glicina/genética
13.
Hum Mol Genet ; 22(5): 927-40, 2013 Mar 01.
Artigo em Inglês | MEDLINE | ID: mdl-23184146

RESUMO

Glycinergic neurotransmission is a major inhibitory influence in the CNS and its disruption triggers a paediatric and adult startle disorder, hyperekplexia. The postsynaptic α(1)-subunit (GLRA1) of the inhibitory glycine receptor (GlyR) and the cognate presynaptic glycine transporter (SLC6A5/GlyT2) are well-established genes of effect in hyperekplexia. Nevertheless, 52% of cases (117 from 232) remain gene negative and unexplained. Ligand-gated heteropentameric GlyRs form chloride ion channels that contain the α(1) and ß-subunits (GLRB) in a 2α(1):3ß configuration and they form the predominant population of GlyRs in the postnatal and adult human brain, brainstem and spinal cord. We screened GLRB through 117 GLRA1- and SLC6A5-negative hyperekplexia patients using a multiplex-polymerase chain reaction and Sanger sequencing approach. The screening identified recessive and dominant GLRB variants in 12 unrelated hyperekplexia probands. This primarily yielded homozygous null mutations, with nonsense (n = 3), small indel (n = 1), a large 95 kb deletion (n = 1), frameshifts (n = 1) and one recurrent splicing variant found in four cases. A further three cases were found with two homozygous and one dominant GLRB missense mutations. We provide strong evidence for the pathogenicity of GLRB mutations using splicing assays, deletion mapping, cell-surface biotinylation, expression studies and molecular modelling. This study describes the definitive assignment of GLRB as the third major gene for hyperekplexia and impacts on the genetic stratification and biological causation of this neonatal/paediatric disorder. Driven principally by consanguineous homozygosity of GLRB mutations, the study reveals long-term additive phenotypic outcomes for affected cases such as severe apnoea attacks, learning difficulties and developmental delay.


Assuntos
Epilepsia/genética , Doenças Genéticas Ligadas ao Cromossomo X/genética , Hipertonia Muscular/genética , Receptores de Glicina/genética , Reflexo Anormal/genética , Adolescente , Adulto , Sequência de Aminoácidos , Criança , Pré-Escolar , Epilepsia/fisiopatologia , Feminino , Doenças Genéticas Ligadas ao Cromossomo X/fisiopatologia , Predisposição Genética para Doença , Proteínas da Membrana Plasmática de Transporte de Glicina/genética , Proteínas da Membrana Plasmática de Transporte de Glicina/metabolismo , Homozigoto , Humanos , Masculino , Dados de Sequência Molecular , Hipertonia Muscular/fisiopatologia , Mutação , Linhagem , Conformação Proteica , Sítios de Splice de RNA/genética , Receptores de Glicina/química , Receptores de Glicina/metabolismo , Relação Estrutura-Atividade
14.
Artigo em Inglês | MEDLINE | ID: mdl-23046880

RESUMO

Gene discovery has been one of the most important advances in our understanding of human disorders. Early linkage and positional cloning strategies have now given way to next generation sequencing (NGS) with age-old help from biostatistical and bioinformatical input. In this chapter, we present the importance of getting the basics right, namely, how the best phenotyping in the clinical domain will provide a higher chance of a successful NGS experiment. In addition, we show getting the correct submission of DNA samples to NGS providers is dependent on the type of inheritance pattern that may or may not be apparent. We discuss one of the most crucial decisions for investigators when designing a study, namely choosing a trio, quad or cohort for analysis. Following on from this, we compare and contrast the underlying technology adopted by provider companies as they vie for customers and submissions. Each platform has advantages and disadvantages based on false calls, coverage, and read depth; however, some of these issues may be solved with the third wave of sequencing technology development in early commercial roll-out. Lastly, we provide a bioinformatic filtering overview of a "quad"-based submission and show how 3 million SNPs and indels can be reduced to a biologically plausible and experimentally manageable n≤50 gene variants.


Assuntos
Proteínas/genética , Análise de Sequência de DNA/métodos , Análise de Sequência de DNA/tendências , Animais , Biologia Computacional , Humanos , Fenótipo , Análise de Sequência de DNA/instrumentação
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...